LAVA Therapeutics N.V. (LVTX)

NASDAQ: LVTX · IEX Real-Time Price · USD
2.95
-0.06 (-1.99%)
Jun 30, 2022 11:35 AM EDT - Market closed

Income Statement (Annual)

Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Year 202120202019
Revenue
53.50
Revenue Growth (YoY)
42.86%--
Gross Profit
53.50
Selling, General & Admin
12.162.721.24
Research & Development
37.1915.78.35
Operating Expenses
49.3518.429.58
Operating Income
-44.35-14.92-9.58
Interest Expense / Income
0.630.340.09
Other Expense / Income
0.210.20.02
Pretax Income
-45.19-15.46-9.69
Income Tax
0.160.040
Net Income
-45.35-15.51-9.69
Net Income Common
-45.35-15.51-9.69
Shares Outstanding (Basic)
2000
Shares Outstanding (Diluted)
2000
Shares Change
4850.36%-10.81%-
EPS (Basic)
-2.30-38.85-21.65
EPS (Diluted)
-2.30-38.85-21.65
Free Cash Flow Per Share
-1.49-24.58-20.95
Gross Margin
100.00%100.00%-
Operating Margin
-887.06%-426.29%-
Profit Margin
-906.94%-443.03%-
Free Cash Flow Margin
-588.22%-280.26%-
Effective Tax Rate
-0.35%-0.28%0.00%
EBITDA
-44.01-14.66-9.34
EBITDA Margin
-880.14%-418.77%-
Depreciation & Amortization
0.560.460.26
EBIT
-44.57-15.12-9.6
EBIT Margin
-891.30%-432.03%-
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).